Clinical Trials Logo

Clinical Trial Summary

The objective of this clinical investigation is to evaluate the efficacy and the safety of the Carmat Total Artificial Heart for the treatment of refractory advanced heart failure in transplant eligible patients.


Clinical Trial Description

A selection committee (composed of two independent experts in the field of cardiovascular surgery/cardiology and of PIs) assess the subject eligibility based on clinical and anatomic criteria. Clinically eligible patients will be distributed into two cohorts depending on their anatomic compatibility with the device: - cohort 1: patients that are anatomically compatible will receive the Carmat TAH ; - cohort 2: patients that are not anatomically compatible will receive standard therapy The efficacy and safety of the Carmat TAH will be assessed in cohort 1 and compared to a level of efficacy defined by the published data on the commercially available TAH; and adjusted for INTERMACS patient profile. The clinical utility and the costs of Carmat TAH will be assessed by comparing the cohort of subject receiving the Carmat TAH to the cohort of patients treated by standard therapy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04475393
Study type Interventional
Source Carmat SA
Contact Soumia Aoualli
Phone +33 63 826 5953
Email clinique@carmatsas.com
Status Recruiting
Phase N/A
Start date December 12, 2022
Completion date April 2027

See also
  Status Clinical Trial Phase
Suspended NCT02962973 - European Clinical Evaluation of the Carmat Total Artificial Heart N/A
Recruiting NCT04915924 - Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea N/A
Completed NCT01626404 - Screening for Advanced Heart Failure Treatment (SEE-HF)
Withdrawn NCT00572286 - Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study N/A
Completed NCT00690157 - Registry of Patients Referred for Heart Transplantation N/A
Active, not recruiting NCT03874312 - Ultrasound-assessed Internal Jugular Vein Distensibility in Advanced Chronic Heart Failure (US-IJVD in CHF)
Enrolling by invitation NCT00988806 - Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure Phase 4
Recruiting NCT05284955 - Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B) Phase 4
Completed NCT01643551 - Neuron Specific Enolase in Ventricular Assist Device Recipients N/A
Terminated NCT04703855 - Hong Kong and Taiwan HM3 PMS N/A
Suspended NCT04851236 - Pilot Study of Massage Therapy to Improve Self Efficacy in Patients With Left-ventricular Device Early Phase 1
Recruiting NCT03526627 - Advanced Care Management in Patients With Advanced Heart Failure
Recruiting NCT06228209 - Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer N/A
Active, not recruiting NCT06259045 - Cardiac Cachexia in Advanced Heart Failure
Recruiting NCT05271214 - Conservative Management of Left Ventricular Assist Device Candidates
Recruiting NCT03911349 - Wrist Worn Blood Pressure Measurement N/A
Recruiting NCT03919136 - Wrist Worn Blood Pressure Measurement
Completed NCT01210573 - Prospective Observation of Exercise Parameters in Advanced Heart Failure N/A
Recruiting NCT04423562 - PROgnostic Value of Exercise Capacity Measured as Peak Oxygen Uptake (pVO2) in Recipients of Left Ventricular Assist Devices